一种治疗性的体外设备，用于从血液中特异性去除病理性不对称二甲基精氨酸。
A Therapeutic Extracorporeal Device for Specific Removal of Pathologic Asymmetric Dimethylarginine from the Blood.
机构信息
Indiana Center for Biomedical Innovation, Indianapolis, Indiana, USA,
Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana, USA.
出版信息
Blood Purif. 2022;51(11):889-898. doi: 10.1159/000522294. Epub 2022 Mar 4.
INTRODUCTION
Blood levels of uremic toxin, asymmetric dimethylarginine (ADMA), are strongly associated with mortality in sepsis, renal failure, and cardiovascular and renal disease patients.
METHODS
An extracorporeal approach to reduce pathological ADMA was developed. The dimethylarginine dimethylaminohydrolase (DDAH) was immobilized on agarose beads to prepare a cartridge. The efficacy of cartridge for ADMA lowering in blood was investigated.
RESULTS
The DDAH beads and cartridge reduced ADMA from solution or plasma. The magnitude of ADMA removal was dependent on the quantity of DDAH linked to the beads and the flow rate. When tested in association with plasmapheresis, the DDAH-cartridge was highly effective in ADMA removal from the blood and improved the arginine/ADMA ratio in a pig model.
CONCLUSION
A new, safe, and effective extracorporeal approach to lower ADMA was developed which may have application in improving outcomes in patients with vascular complications and risk of mortality associated with high ADMA.
简介
尿毒症毒素、不对称二甲基精氨酸（ADMA）的血液水平与败血症、肾衰竭以及心血管和肾脏疾病患者的死亡率密切相关。
方法
开发了一种体外方法来降低病理性 ADMA。将二甲基精氨酸二甲氨基水解酶（DDAH）固定在琼脂糖珠上以制备试剂盒。研究了试剂盒在降低血液中 ADMA 方面的效果。
结果
DDAH 珠和试剂盒可降低溶液或血浆中的 ADMA。ADMA 的去除程度取决于与珠相连的 DDAH 的数量和流速。当与血浆置换一起测试时，DDAH 试剂盒在从血液中有效去除 ADMA 并提高猪模型中的精氨酸/ADMA 比值方面非常有效。
结论
开发了一种新的、安全有效的体外方法来降低 ADMA，这可能有助于改善血管并发症患者的预后，并降低与高 ADMA 相关的死亡率风险。
Zotero 插件